- Home
- OCGN vs TLSI Comparison
OCGN vs TLSI Comparison
Compare OCGN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- TLSI
- Stock Information
- Founded
- OCGN 2013
- TLSI 2010
- Country
- OCGN United States
- TLSI United States
- Employees
- OCGN N/A
- TLSI N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- TLSI Medical Specialities
- Sector
- OCGN Health Care
- TLSI Health Care
- Exchange
- OCGN Nasdaq
- TLSI Nasdaq
- Market Cap
- OCGN 189.6M
- TLSI 160.4M
- IPO Year
- OCGN N/A
- TLSI N/A
- Fundamental
- Price
- OCGN $0.68
- TLSI $5.74
- Analyst Decision
- OCGN Strong Buy
- TLSI Strong Buy
- Analyst Count
- OCGN 3
- TLSI 6
- Target Price
- OCGN $6.33
- TLSI $11.75
- AVG Volume (30 Days)
- OCGN 4.3M
- TLSI 57.4K
- Earning Date
- OCGN 05-13-2025
- TLSI 05-14-2025
- Dividend Yield
- OCGN N/A
- TLSI N/A
- EPS Growth
- OCGN N/A
- TLSI N/A
- EPS
- OCGN N/A
- TLSI N/A
- Revenue
- OCGN $4,054,999.00
- TLSI $29,431,000.00
- Revenue This Year
- OCGN N/A
- TLSI $55.08
- Revenue Next Year
- OCGN N/A
- TLSI $50.75
- P/E Ratio
- OCGN N/A
- TLSI N/A
- Revenue Growth
- OCGN N/A
- TLSI 58.99
- 52 Week Low
- OCGN $0.52
- TLSI $3.50
- 52 Week High
- OCGN $2.06
- TLSI $10.24
- Technical
- Relative Strength Index (RSI)
- OCGN 51.84
- TLSI 59.91
- Support Level
- OCGN $0.64
- TLSI $5.23
- Resistance Level
- OCGN $0.74
- TLSI $5.66
- Average True Range (ATR)
- OCGN 0.07
- TLSI 0.34
- MACD
- OCGN 0.00
- TLSI 0.03
- Stochastic Oscillator
- OCGN 54.50
- TLSI 92.94
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.